Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
The seven-year analysis of the CROWN trial shows a 55% likelihood of remaining alive without disease progression for patients treated with LORBRENA, with median progression-free survival not reached.
Phase III
Non-Small Cell Lung Cancer
Status
Active
Sponsor
Pfizer
Signal Score
9.6
Signal assessment
Signal strength
critical
Confidence level
high
Why it matters
The seven-year results from the CROWN trial position LORBRENA as a leading treatment option for advanced NSCLC, significantly impacting clinical practice and competitive dynamics in the oncology space. This data not only enhances Pfizer's market position but also sets a new standard for treatment expectations in this patient population.
Recommended action
Humanexa recommends Escalate: The recommended action to escalate is warranted due to the high impact of these results on clinical practice and competitive positioning, necessitating immediate attention from leadership to strategize responses and capitalize on this data.
Analysis
Monitor for further data on overall survival and additional long-term outcomes from the CROWN trial, as well as competitive responses from other ALK inhibitors.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Source links
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.